MOTS-c and SS-31: What Researchers Need to Know About These Mitochondrial Peptides

If you searched for 'mots c and ss 31,' you are likely asking about two research peptides: MOTS-c and SS-31. They both target mitochondrial function, but they are not the same molecule. MOTS-c is a mitochondrial-derived peptide involved in metabolic regulation, while SS-31 (elamipretide) is a synthetic tetrapeptide that binds to the inner mitochondrial membrane. Neither is FDA-approved for human use, and both are sold strictly for research purposes.

What Is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. It was first described in 2015 and belongs to a class of molecules called mitochondrial-derived peptides. Preclinical studies suggest MOTS-c helps regulate insulin sensitivity, metabolic homeostasis, and the body's response to exercise.

MOTS-c is sometimes called a mitokine because it can travel to other tissues and influence metabolism. It is thought to act through the AMPK pathway, which is a cellular energy sensor. In animal models, MOTS-c has been linked to improved glucose metabolism and reduced age-related metabolic decline. Human data remain very limited. MOTS-c is not approved as a drug, and its long-term effects in humans are unknown.

What Is SS-31?

SS-31, also known as elamipretide, is a synthetic tetrapeptide designed to concentrate in the inner mitochondrial membrane. It was engineered to reduce reactive oxygen species (ROS) and improve mitochondrial bioenergetics. SS-31 has been studied in clinical trials for conditions such as Barth syndrome, heart failure, and age-related mitochondrial dysfunction.

SS-31's ability to target cardiolipin, a phospholipid found in the inner mitochondrial membrane, is central to its proposed mechanism. By stabilizing cardiolipin, SS-31 may help preserve mitochondrial structure and function under stress. Despite years of research, SS-31 is not FDA-approved for any indication. It remains an investigational compound. Researchers often explore ss-31 peptide benefits and side effects to understand its therapeutic potential and limitations.

MOTS-c vs. SS-31: Key Differences

The two peptides differ in origin, structure, and mechanism of action. The table below summarizes the main distinctions.

Can You Take SS-31 and MOTS-c Together?

Some researchers investigate an ss-31 and mots-c protocol to see whether their mitochondrial effects complement each other. A common question is, can you take ss-31 and mots-c together? There is no published human trial that evaluates an ss-31 and mots-c stack.

In theory, ss-31 and mots-c together might support different aspects of mitochondrial function, but this is speculative. Most available data come from cell and animal models. Without human safety data, combining them is experimental and carries unknown risks.

Potential Benefits and Side Effects

SS-31 peptide benefits and side effects have been studied mainly in clinical trials for rare mitochondrial diseases. Reported benefits include improved mitochondrial function and reduced oxidative stress. Side effects in trials have included injection site reactions, headache, and nausea.

MOTS-c has shown metabolic benefits in rodents, including improved insulin sensitivity and enhanced fat oxidation. Human side effect data for MOTS-c are lacking. General research-peptide risks include injection site irritation, immune reactions, and unknown long-term effects.

• Potential MOTS-c benefits: better glucose handling, increased fat burning, improved exercise capacity (animal models).
• Potential SS-31 benefits: reduced oxidative stress, improved cardiac and mitochondrial function.
• Reported side effects: injection site reactions, fatigue, gastrointestinal upset, headache.
• Unknown risks: long-term immune effects, organ toxicity, interactions with other compounds.

Typical research dosages for SS-31 in animal studies range from 1 to 5 mg/kg per day, but human equivalent doses are not established. MOTS-c dosages in animal research vary widely, and no safe human dose has been determined.

Legal Status and Safety Considerations

MOTS-c and SS-31 are not FDA-approved for human use in the United States. They are sold as research chemicals, and their purity, sterility, and potency are not guaranteed. Researchers should follow institutional and legal guidelines when handling them.

The FDA has issued warnings about unapproved peptides sold online. Some products labeled as MOTS-c or SS-31 may be mislabeled or contaminated. Anyone considering these peptides for personal use should consult a healthcare professional. Self-administration of unapproved peptides can lead to infection, allergic reaction, and other serious health consequences.

Bottom Line

MOTS-c and SS-31 are distinct mitochondrial peptides with different mechanisms. MOTS-c is an endogenous metabolic regulator, while SS-31 is a synthetic mitochondria-targeted antioxidant. There is no human evidence that combining them is safe or effective. Always prioritize safety, legality, and professional medical advice.